Valneva (VALN) Competitors $6.07 +0.06 (+1.00%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$6.09 +0.02 (+0.31%) As of 07/11/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. IDYA, IRON, BLTE, CNTA, HRMY, ADPT, SRPT, TARS, IMCR, and ARQTShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Sarepta Therapeutics Tarsus Pharmaceuticals Immunocore Arcutis Biotherapeutics IDEAYA Biosciences (NASDAQ:IDYA) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment. Do institutionals & insiders have more ownership in IDYA or VALN? 98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is IDYA or VALN more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Valneva's net margin of -43.08%. IDEAYA Biosciences' return on equity of -29.28% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -29.28% -27.68% Valneva -43.08%-43.05%-16.23% Which has better earnings & valuation, IDYA or VALN? Valneva has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M281.26-$274.48M-$3.59-6.26Valneva$183.52M2.81-$13.25M-$1.19-5.10 Does the media favor IDYA or VALN? In the previous week, IDEAYA Biosciences had 4 more articles in the media than Valneva. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 4 mentions for Valneva. Valneva's average media sentiment score of 0.96 beat IDEAYA Biosciences' score of 0.87 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, IDYA or VALN? IDEAYA Biosciences has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Do analysts prefer IDYA or VALN? IDEAYA Biosciences presently has a consensus target price of $47.55, indicating a potential upside of 111.50%. Valneva has a consensus target price of $15.50, indicating a potential upside of 155.35%. Given Valneva's stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.85Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryValneva beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$511.42M$10.60B$5.60B$9.11BDividend YieldN/A2.07%5.24%4.02%P/E Ratio-5.1016.2727.9620.25Price / Sales2.8130.15430.8999.65Price / Cash61.5122.9637.4658.16Price / Book2.523.668.045.49Net Income-$13.25M$235.43M$3.18B$250.27M7 Day Performance6.19%1.27%3.63%4.75%1 Month Performance-1.30%2.95%4.04%7.64%1 Year Performance-20.03%-15.74%29.55%16.34% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva1.8296 of 5 stars$6.07+1.0%$15.50+155.4%-18.3%$511.42M$183.52M-5.10700News CoverageIDYAIDEAYA Biosciences3.613 of 5 stars$21.16-4.3%$53.73+153.9%-43.3%$1.94B$7M-5.8980News CoverageAnalyst UpgradeIRONDisc Medicine3.2092 of 5 stars$53.38-2.5%$96.70+81.2%+21.3%$1.90BN/A-13.6230Insider TradeBLTEBelite Bio2.3587 of 5 stars$58.63-1.4%$96.67+64.9%+29.2%$1.89BN/A-43.1110News CoverageAnalyst RevisionCNTACentessa Pharmaceuticals3.2499 of 5 stars$13.62-3.2%$27.89+104.8%+50.8%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8611 of 5 stars$32.24+0.2%$53.63+66.3%+2.0%$1.85B$714.73M12.31200News CoveragePositive NewsAnalyst ForecastADPTAdaptive Biotechnologies2.8637 of 5 stars$11.74-0.5%$10.57-10.0%+203.9%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.7103 of 5 stars$17.32-5.0%$60.88+251.5%-88.1%$1.79B$1.90B-6.441,372Trending NewsAnalyst ForecastAnalyst RevisionTARSTarsus Pharmaceuticals2.0378 of 5 stars$39.93-3.0%$66.67+67.0%+31.0%$1.73B$182.95M-14.6350Positive NewsIMCRImmunocore1.4516 of 5 stars$32.41-1.8%$58.89+81.7%-11.1%$1.66B$310.20M-75.37320News CoverageARQTArcutis Biotherapeutics1.9613 of 5 stars$13.39-3.1%$18.80+40.4%+39.9%$1.65B$196.54M-12.88150News Coverage Related Companies and Tools Related Companies IDYA Alternatives IRON Alternatives BLTE Alternatives CNTA Alternatives HRMY Alternatives ADPT Alternatives SRPT Alternatives TARS Alternatives IMCR Alternatives ARQT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
